Phase III, randomised, open-label, active-controlled, multicentre, parallel-group study to assess the non-inferior antiviral activity and safety of a two-drug regimen of dolutegravir and lamivudine compared to continuation on a TAF-based regimen in HIV-infected adults who are virologically suppressed and stable on a TAF-based regimen.
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2018
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms TANGO
- 13 Feb 2018 New trial record
- 08 Feb 2018 According to a GlaxoSmithKline media release, results are expected in 2019.